A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The IL-23 inhibitor risankizumab proved to be safe and efficacious after 52 weeks of treatment in patients with ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Most patients with moderate to severe CD who did not initially respond to risankizumab achieved clinical response after extension. Delayed responders also demonstrated clinical and endoscopic ...

AbbVie’s psoriasis drug risankizumab has posted strong results in its latest phase 3 trial, as the company prepares to file the drug with global regulators. An interleukin-23 inhibitor ...

Several medications now calm painful inflammation in the intestines. Diets free of ultraprocessed foods also help ...

The European Commission (EC) has granted marketing authorization to Rinvoq (upadacitinib; 15mg, once daily), from US pharma ...

risankizumab, guselkumab, and ustekinumab, with implications for clinical decision-making based on early versus late disease onset and prior biologic exposure. n = 113 early onset (first diagnosis ...

In this uncontrolled study, patients with severe psoriasis (involved body surface area over 10%) were enrolled and treated with the IL-23 inhibitor risankizumab. Rather than the standard dose ...

Yet, unlike its IL-23p19 predecessors — Skyrizi (risankizumab, AbbVie) and Omvoh (mirikizumab, Eli Lilly & Co.) — Tremfya is the only one to demonstrate clinical superiority to the IL-12/23 ...

In head-to-head preclinical studies, SPY003 demonstrated equivalent potency to risankizumab in inhibiting pSTAT signaling and IL-17 production and exhibited significantly longer half-life in non ...

Discover the latest drugs and treatment options in the Psoriasis Pipeline. Dive into DelveInsight's comprehensive report ...